The U.S. Food and Drug Administration (FDA) has proposed a new policy that reduces premarket notification requirements related to devices that have had their safety and efficacy well proven, for example, blood clotting tests and common urine and blood tests. Read more.
FDA proposes new policy for some devices
Share